Report Description Table of Contents Human Chorionic Gonadotropin Market: Fertility Demand Meets Recombinant Growth – (Updated On: 3rd-Oct-2026) The Global Human Chorionic Gonadotropin (hCG) Market was valued at USD 1.11 billion in 2025 and is projected to reach USD 1.72 billion by 2032, expanding at a 6.5% CAGR. hCG is used primarily in female fertility treatment, assisted reproductive technology (ART), and selected male hypogonadotropic hypogonadism and infertility treatments. Fertility remains a major demand source. In women, hCG is commonly administered to trigger final follicular maturation and ovulation during fertility treatment and IVF cycles. Male treatment typically involves repeated dosing to stimulate endogenous testosterone production and support testicular function and spermatogenesis in appropriate patients, creating a different utilization pattern from single-dose fertility triggers. The commercial market includes both urinary-derived and recombinant hCG. Established products include Pregnyl, Novarel, and recombinant Ovidrel (choriogonadotropin alfa), alongside products supplied by international manufacturers. Recombinant formulations provide advantages in purity, consistency, and standardized manufacturing, supporting their growing role in fertility protocols. Market growth through 2032 will be supported by expanding fertility treatment and ART volumes, greater access to reproductive care, male infertility treatment, and continued adoption of standardized recombinant products. Regulatory treatment of hCG as a biologic in the United States also strengthens the role of licensed commercial manufacturers relative to traditional compounded supply. Established Revenue Leaders and the Next Phase of hCG Growth By Product Type: Urinary hCG Leads as Recombinant Formulations Gain Ground Leading Subsegment – Urinary-Derived hCG (u-hCG) Urinary-derived human chorionic gonadotropin (u-hCG) accounted for an estimated 72.0% of the Human Chorionic Gonadotropin Market, representing approximately USD 0.799 billion in 2025 revenue, and is projected to reach nearly USD 1.18 billion by 2032 at a CAGR of 5.70% during 2026–2032. Its established use as an LH surrogate for triggering final oocyte maturation and ovulation in IVF and ICSI procedures, along with applications in luteal support and male hypogonadotropic hypogonadism, continues to sustain clinical demand despite greater batch variability than recombinant hCG. Fastest-Growing Subsegment – Recombinant hCG (r-hCG) Recombinant human chorionic gonadotropin (r-hCG) accounted for approximately 28.0% of the Human Chorionic Gonadotropin Market, representing USD 0.311 billion in 2025, and is projected to expand at the fastest product CAGR of 8.40% during 2026–2032, reaching nearly USD 0.55 billion by 2032. Its growth is supported by increasing use in assisted reproductive technologies to trigger final oocyte maturation and ovulation, along with its high purity, consistent dosing, convenient subcutaneous administration, and comparable clinical efficacy to urinary hCG preparations. By Application & Therapeutic Area: Female Fertility Care Anchors hCG Revenue Leading and Fastest-Growing Subsegment – Female Infertility Treatment Female infertility treatment dominates the Human Chorionic Gonadotropin Market with an estimated 66.0% share, generating USD 0.733 billion in 2025, and is projected to exceed USD 1.15 billion by 2032 at a 6.70% CAGR during 2026–2032. hCG plays a critical role in fertility therapy by triggering ovulation, supporting corpus luteum function, and improving endometrial readiness. Its use across ovulation induction, timed intercourse, IUI, and IVF procedures continues to support sustained demand within assisted reproductive treatment protocols. By Distribution Channel: Hospital Leadership Meets Faster Digital Access Leading Subsegment – Hospital Pharmacies Hospital pharmacies account for approximately 58.0% of the Human Chorionic Gonadotropin market, generating nearly USD 0.644 billion in 2025 revenue. The segment is projected to expand at a 6.10% CAGR during 2026–2032, reaching about USD 0.98 billion by 2032. Their strong position reflects their role in procuring, storing, and dispensing approved hCG therapies for fertility treatment and male hypogonadism, while supporting cold-chain management, accurate dosing, patient counseling, and clinical monitoring in coordination with reproductive endocrinology and urology teams. Fastest-Growing Subsegment – Online Pharmacies Online pharmacies account for approximately 13.0% of Human Chorionic Gonadotropin Market revenue in 2025, equivalent to USD 0.144 billion, and are projected to expand at the fastest distribution CAGR of 8.80% through 2032, potentially reaching around USD 0.26 billion. Growth is supported by increasing digital access to hCG therapies for fertility treatment and endocrine care. E-prescriptions, tele-fertility platforms, home delivery, greater privacy, and improved access to specialized hCG products are strengthening online pharmacies as an important distribution channel. By Geography: North America Leads as Asia-Pacific Accelerates Leading Region – North America North America is a leading market for Human Chorionic Gonadotropin (hCG), supported by advanced healthcare infrastructure, high reproductive-health awareness, and widespread use of assisted reproductive technologies. The region accounted for an estimated 38.0% of the global hCG market in 2025, generating approximately USD 0.422 billion in revenue. Rising fertility treatment volumes and sustained clinical use of hCG are expected to support a 5.90% CAGR during 2026–2032, taking the regional market to nearly USD 0.63 billion by 2032. Fastest-Growing Region – Asia-Pacific Asia-Pacific represents an estimated 23.0% share of the Human Chorionic Gonadotropin (hCG) Market, equivalent to approximately USD 0.255 billion in 2025 revenue. The regional market is projected to expand at the fastest CAGR of 8.20% during 2026–2032, reaching nearly USD 0.44 billion by 2032. Adoption of Human Chorionic Gonadotropin (hCG) is increasing rapidly across Asia-Pacific, supported by expanding fertility treatment services, rising use of assisted reproductive technologies, growing reproductive healthcare access, and increasing demand for hCG-based therapies across fertility clinics and hospitals. Fertility Portfolios and hCG Product Breadth Shape Competitive Strength Merck KGaA / EMD Serono – Strong Position in Recombinant hCG and Integrated IVF Therapy Merck KGaA, operating as EMD Serono in the United States and Canada, is one of the most prominent participants in fertility therapeutics. Its Ovidrel® prefilled syringe contains 250 mcg of recombinant choriogonadotropin alfa, positioning the company directly in the higher-value recombinant hCG segment used for final follicular maturation during fertility treatment. EMD Serono has worked in fertility innovation for more than 40 years and markets a complementary U.S. fertility portfolio consisting of Ovidrel, Gonal-f, and Cetrotide, allowing the company to participate across several stages of an IVF treatment cycle. In February 2026, the company also expanded U.S. access to its complete IVF medicine portfolio through new direct patient-access pathways, strengthening its commercial reach in one of the world's largest fertility-treatment markets. Ferring Pharmaceuticals – Broad Human-Derived Gonadotropin and ART Portfolio Ferring maintains a substantial position in reproductive medicine through CHORAGON®/BREVACTID® urinary-derived hCG, which is used to trigger ovulation after follicular stimulation and can also be combined with MENOPUR in the treatment of male infertility associated with hypogonadism. Ferring's 2025 annual report identifies highly purified hCG products including Chorapur/Brevactid and Novarel within its reproductive-medicine portfolio. The company's broader fertility platform also includes MENOPUR and REKOVELLE, giving it exposure across ovarian stimulation, ovulation triggering, and ART. Ferring states that it has been developing treatments for mothers and babies for more than 50 years, supporting its established clinical and commercial presence in reproductive healthcare. Sun Pharmaceutical Industries – Strong hCG Availability Across Multiple Dosage Strengths Sun Pharma has an important competitive role, particularly in India and other price-sensitive pharmaceutical markets, through its Fertigyn and Fertigyn HP human chorionic gonadotropin injections. Its official Indian product portfolio lists Fertigyn in 5,000 IU and 10,000 IU strengths and Fertigyn HP in 2,000 IU, 5,000 IU, and 10,000 IU strengths, along with Fertigyn R. This broad range allows physicians to access different hCG dosing options across fertility and hormone-treatment protocols. Sun Pharma's documented product pricing also confirms active commercial availability of the Fertigyn HP range, strengthening its role in the urinary-derived and affordable hCG treatment segment. Other Notable Human Chorionic Gonadotropin Market Participants Bharat Serums and Vaccines: Participates through HUCOG/HP-hCG and recombinant hCG; India's CDSCO documented an already approved 6,500 IU recombinant hCG injection while reviewing an additional proposed 3,250 IU strength in June 2025. Fresenius Kabi: Supplies Chorionic Gonadotropin for Injection, USP, 10,000 units per vial in the U.S.; FDA records identify an active prescription presentation under Fresenius Kabi USA. IBSA Institut Biochimique: Competes through Zivafert, a highly purified urinary-derived hCG manufactured in Switzerland and indicated for ovulation triggering and final follicular maturation in ART/IVF. Organon: Maintains an established hCG presence through Pregnyl® (chorionic gonadotropin) for injection, which remains listed within the company's current prescription product portfolio. Analyst Commentary: Recombinant hCG and Wider Fertility Access Open New Growth Paths The Human Chorionic Gonadotropin Market is shifting toward a more specialized fertility-treatment landscape, with recombinant hCG gaining importance alongside established urinary-derived formulations. The strongest commercial opportunities are emerging from expanding IVF and assisted reproductive technology cycles, rising infertility treatment access in Asia-Pacific, greater use of standardized high-purity hormone therapies, and broader digital and specialty-pharmacy distribution. Human Chorionic Gonadotropin Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 1.11 Billion Revenue Forecast in 2032 USD 1.72 Billion Overall Growth Rate CAGR of 6.5% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Product Type, By Application & Therapeutic Area, By Distribution Channel, By Geography By Product Type Urinary-Derived hCG (u-hCG), Recombinant hCG (r-hCG) By Application & Therapeutic Area Female Infertility Treatment, Male Hypogonadism & Cryptorchidism, Diagnostics & Oncology, Other Applications By Distribution Channel Hospital Pharmacies, Retail Pharmacies, Online Pharmacies By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Expanding fertility treatment and ART volumes, increasing access to reproductive healthcare, rising male infertility treatment demand, growing adoption of standardized recombinant hCG products, expanding IVF infrastructure, and increasing digital and specialty-pharmacy access to fertility therapies Customization Option Available upon request Frequently Asked Question About This Report Q1: What are the main factors driving growth in the market? A1: Growth is being supported by expanding fertility treatment and IVF volumes. Greater access to reproductive care and continued use of hCG in selected male infertility cases are also widening the treatment base. Q2: What are the key trends shaping the industry? A2: The industry is moving toward higher-purity recombinant formulations and more standardized fertility protocols. Digital prescription fulfillment and broader access through specialty and online pharmacies are also becoming more important. Q3: Why is recombinant therapy gaining importance in the market? A3: Recombinant hCG is gaining importance because it offers consistent potency, high purity, and controlled manufacturing. These features are especially valuable in assisted reproductive procedures where precise dosing and predictable treatment response are important. Q4: Which applications are generating the strongest demand in the industry? A4: Female infertility treatment remains the largest application area. Ovulation triggering, IVF, IUI, and final follicular maturation continue to generate the strongest demand, while male hypogonadism and infertility also contribute to long-term treatment use. Q5: How are distribution channels changing across the market? A5: Hospital pharmacies remain the largest channel, but online pharmacies are expanding faster. E-prescriptions, home delivery, tele-fertility services, and easier access to specialty medicines are supporting this shift. Q6: Which region is expected to record the fastest growth in the industry? A6: Asia-Pacific is projected to record the fastest CAGR of 8.20% during 2026–2032. Growth is supported by expanding IVF capacity, rising infertility treatment demand, and improving access to reproductive healthcare across China, India, and Japan. Q7: What opportunities are expected to shape the future of the market? A7: Future opportunities are concentrated around recombinant hCG, broader ART adoption, male fertility treatment, and digital fertility-care pathways. Increasing access to standardized hormone therapies in emerging healthcare markets could further support demand. Sources: CDC – Assisted Reproductive Technology (ART) Surveillance and U.S. Fertility Treatment Volumes CDC ART Surveillance U.S. FDA – Ovidrel (Choriogonadotropin Alfa) Recombinant hCG Prescribing Information FDA Ovidrel Prescribing Information EMD Serono – Ovidrel 250 mcg Recombinant hCG Prefilled Syringe EMD Serono Ovidrel Organon – Pregnyl (Human Chorionic Gonadotropin) Product Information Organon Pregnyl Product Portfolio U.S. FDA – Novarel (Urinary-Derived Human Chorionic Gonadotropin) Approval and Label FDA Novarel Approval U.S. FDA – hCG Transition to Regulation as a Biological Product FDA hCG Biologic Regulation Guidance CDSCO – Bharat Serums Recombinant hCG 6,500 IU and Proposed 3,250 IU Strength CDSCO Recombinant hCG Regulatory Record Fresenius Kabi – Chorionic Gonadotropin for Injection, USP 10,000 Units Fresenius Kabi hCG Product Information Table of Contents - Global Human Chorionic Gonadotropin Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Application & Therapeutic Area, Distribution Channel, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Application & Therapeutic Area, Distribution Channel, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Application & Therapeutic Area, and Distribution Channel Investment Opportunities in the Human Chorionic Gonadotropin Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Recombinant hCG, Assisted Reproductive Technology, Female Infertility Treatment, Male Hypogonadism & Cryptorchidism, and Digital Fertility-Medicine Distribution Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Human Chorionic Gonadotropin in Fertility Treatment, Assisted Reproductive Technology, Male Reproductive Health, and Selected Diagnostic Applications Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Manufacturing Compliance Factors Role of Female Infertility Treatment, Assisted Reproductive Technology, Male Hypogonadism & Cryptorchidism, Diagnostics & Oncology, and Specialty Fertility Care in Market Expansion Role of Recombinant Manufacturing, Purity, Standardized Potency, Prescription Access, Cold-Chain Management, and Digital Pharmacy Models in hCG Market Development Global Human Chorionic Gonadotropin Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Urinary-Derived hCG (u-hCG) Recombinant hCG (r-hCG) Market Analysis by Application & Therapeutic Area: Female Infertility Treatment Male Hypogonadism & Cryptorchidism Diagnostics & Oncology Other Applications Market Analysis by Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Market Analysis by Geography: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Human Chorionic Gonadotropin Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application & Therapeutic Area, and Distribution Channel Country-Level Breakdown: United States Canada Europe Human Chorionic Gonadotropin Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application & Therapeutic Area, and Distribution Channel Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Human Chorionic Gonadotropin Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application & Therapeutic Area, and Distribution Channel Country-Level Breakdown: China Japan South Korea India Australia Rest of Asia-Pacific Latin America Human Chorionic Gonadotropin Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application & Therapeutic Area, and Distribution Channel Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Human Chorionic Gonadotropin Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application & Therapeutic Area, and Distribution Channel Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Merck KGaA / EMD Serono Ferring Pharmaceuticals Sun Pharmaceutical Industries Ltd. Bharat Serums and Vaccines Ltd. Fresenius Kabi IBSA Institut Biochimique SA Organon & Co. Intas Pharmaceuticals Ltd. Cipla Ltd. Dr. Reddy’s Laboratories Ltd. Zydus Lifesciences Ltd. Competitive Landscape and Strategic Insights Benchmarking Based on Recombinant and Urinary-Derived Product Positioning, Product Purity, Standardized Potency, Manufacturing Consistency, Distribution Reach, Fertility Portfolio Breadth, and Regional Presence Supplier Qualification, Regulatory Compliance, Manufacturing Capability, and Product Availability Analysis Recombinant hCG Positioning and Fertility-Clinic Adoption Strategy Female Infertility Treatment and Assisted Reproductive Technology Competitiveness Male Hypogonadism & Cryptorchidism Treatment Positioning Strategy Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy Distribution Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Product Type, Application & Therapeutic Area, Distribution Channel, and Geography (2026–2032) Regional Market Breakdown by Product Type, Application & Therapeutic Area, and Distribution Channel (2026–2032) Competitive Benchmarking of Leading Human Chorionic Gonadotropin Vendors Regulatory Compliance, Manufacturing, and Procurement Risk Analysis Distribution and Treatment Access Trends Across Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Application & Therapeutic Area, Distribution Channel, and Geography (2025 vs. 2032) Global Human Chorionic Gonadotropin Ecosystem and Value Chain Analysis